KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Equivalents: 2018-2024

Historic Cash & Equivalents for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $144.8 million.

  • Esperion Therapeutics' Cash & Equivalents fell 36.12% to $92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.4 million, marking a year-over-year decrease of 36.12%. This contributed to the annual value of $144.8 million for FY2024, which is 76.01% up from last year.
  • Esperion Therapeutics' Cash & Equivalents amounted to $144.8 million in FY2024, which was up 76.01% from $82.2 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Cash & Equivalents ranged from a high of $305.0 million in FY2020 and a low of $82.2 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $117.3 million, with a median of $124.8 million in 2022.
  • In the last 5 years, Esperion Therapeutics' Cash & Equivalents surged by 83.57% in 2020 and then plummeted by 40.27% in 2022.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Cash & Equivalents stood at $305.0 million in 2020, then crashed by 31.50% to $208.9 million in 2021, then tumbled by 40.27% to $124.8 million in 2022, then crashed by 34.08% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024.